Compugen Ltd at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
All right. So it's 9:10. Let's go ahead and get started with day 2 of the Oppenheimer Fall Healthcare and MedTech Summit (sic) [Fall Healthcare Life Sciences & MedTech Summit]. My name is Mark Breidenbach. And I'm pleased to introduce our next presenting company, Compugen Ltd., based out of Holon, Israel and South San Francisco, California.
Joining us this morning to walk us through the story, we have Compugen's CEO, Anat Cohen-Dayag. And for those new to the story, Compugen is a clinical stage therapeutics company focused on drugging novel immune checkpoints with applications in oncology and autoimmune disease.
The company's lead program, COM701, has demonstrated monotherapy activity in a Phase I dose escalation trial and is currently being evaluated in expansion cohorts focusing on specific tumor types. COM701 also recently entered into an all-comers triple combination trial with Bristol-Myers Squibb's TIGIT antibody and PD-1 checkpoint antibody. As Anat will explain,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
